Samid D, Hudgins W R, Shack S, Liu L, Prasanna P, Myers C E
Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
Adv Exp Med Biol. 1997;400A:501-5. doi: 10.1007/978-1-4615-5325-0_67.
Phenylacetate and analogs represent a new class of pleiotropic growth regulators that alter tumor cell biology by affecting gene expression at both the transcriptional and post transcriptional levels. Based on these findings, NaPA and NaPB entered clinical trials at the National Cancer Institute. Ongoing phase I studies with NaPA, involving adults with prostate and brain cancer, have confirmed that therapeutic levels can be achieved with no significant toxicities, and provide preliminary evidence for benefit to patients with advanced disease (Thibault et al., submitted).
苯乙酸及其类似物代表了一类新型的多效生长调节剂，它们通过在转录和转录后水平影响基因表达来改变肿瘤细胞生物学特性。基于这些发现，苯丁酸钠和苯甲酸钠进入了美国国立癌症研究所的临床试验。正在进行的苯丁酸钠I期研究涉及前列腺癌和脑癌成年患者，已证实可以达到治疗水平且无明显毒性，并为晚期疾病患者带来益处提供了初步证据（蒂博等，待发表）。
